

Information Regarding Clinical Trial

| | |
|------------------------------------|---|
| Title | A phase 1B/2 study to evaluate safety and anti-tumor activity of avelumab in combination with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor talazoparib in patients with locally advanced or metastatic solid tumors |
| Protocol Number | B9991025 |
| Sponsor | Pfizer |
| Investigator | J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703 |
| Study Related Phone Numbers | 479-587-1700 (24 hours) |
| Key Points for Study | <p><u>NSCLC</u>: 0-2 prior platinum tx, EGFR/ALK/ROS1-</p> <p><u>TNBC</u>: at least 1 prior chemo</p> <p><u>Ovarian</u>: at least 1 prior platinum</p> <p><u>Trans. Cell Urothelium</u>: at least 1 prior platinum</p> <p><u>CRPC</u>: 1-2 prior chemo, at least 1 taxane, at least 1 hormonal tx</p> <p>-If prior plat, must not have progression on tx</p> <p>-No prior immunotherapy</p> <p>**MUST REQUEST SLOT BEFORE PT CONTACT**</p> |